Evidence map›Paper›PMID 37186921›Full record

ReviewAnnals of internal medicine2023

Improving COVID-19 Disease Severity Surveillance Measures: Statewide Implementation Experience.

Shira Doron, Paul A Monach, Catherine M Brown, Westyn Branch-Elliman

Open access · greenAbstract readReview
In one paragraph

Review in Annals of internal medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Observational
  4. Pulmonary aspergillosis in US Veterans with COVID-19: a nationwide, retrospective cohort study.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2025
    Article
  5. Misattribution Bias of COVID-19 Hospitalizations in Alberta Using an Admission Algorithm.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2024
    Article
  6. Article
  7. Article
  8. SARS-CoV-2 Case-Definitions Must Include Clinical Criteria: Reply to Kojima et al.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Shira DoronDivision of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, Massachusetts (S.D.).
Paul A MonachRheumatology Section, Veterans Affairs Boston Healthcare System, and Harvard Medical School, Boston, Massachusetts (P.A.M.).
Catherine M BrownMassachusetts Department of Public Health, Boston, Massachusetts (C.M.B.).
Westyn Branch-EllimanHarvard Medical School; Department of Medicine, Veterans Affairs Boston Healthcare System; and Veterans Affairs Boston Center for Healthcare Organization and Implementation Research (CHOIR), Boston, Massachusetts (W.B.).ORCID 0000-0002-9658-5124
Harvard University · USMassachusetts Department of Public Health · USTufts Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Measurement of the burden of COVID-19 on U.S. hospitals has been an important element of the public health response to the pandemic. However, because of variation in testing density and policies, the metric is not standardized across facilities. Two types of burdens exist, one related to the infection control measures that patients who test positive for SARS-CoV-2 require and one from the care of severely ill patients receiving treatment of COVID-19. With rising population immunity from vaccination and infection, as well as the availability of therapeutics, severity of illness has declined. Prior research showed that dexamethasone administration was highly correlated with other disease severity metrics and sensitive to the changing epidemiology associated with the emergence of immune-evasive variants. On 10 January 2022, the Massachusetts Department of Public Health began requiring hospitals to expand surveillance to include reports of both the total number of "COVID-19 hospitalizations" daily and the number of inpatients who received dexamethasone at any point during their hospital stay. All 68 acute care hospitals in Massachusetts submitted COVID-19 hospitalization and dexamethasone data daily to the Massachusetts Department of Public Health over a 1-year period. A total of 44 196 COVID-19 hospitalizations were recorded during 10 January 2022 to 9 January 2023, of which 34% were associated with dexamethasone administration. The proportion of patients hospitalized with COVID-19 who had received dexamethasone was 49.6% during the first month of surveillance and decreased to a monthly average of approximately 33% by April 2022, where it has remained since (range, 28.7% to 33%). Adding a single data element to mandated reporting to estimate the frequency of severe COVID-19 in hospitalized patients was feasible and provided actionable information for health authorities and policy makers. Updates to surveillance methods are necessary to match data collection with public health response needs.

Indexed as

COVID-19DexamethasoneHospitalsHumansPatient AcuitySARS-CoV-2Dexamethasone

Identifiers

PMID37186921
PMCPMC10308638
OpenAlexW4376602419

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.